United Services Automobile Association Invests $255,000 in ADMA Biologics, Inc. (NASDAQ:ADMA)

United Services Automobile Association bought a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 14,882 shares of the biotechnology company's stock, valued at approximately $255,000.

Several other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of ADMA Biologics by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company's stock valued at $312,109,000 after purchasing an additional 80,302 shares during the last quarter. Simplify Asset Management Inc. bought a new stake in ADMA Biologics during the 4th quarter valued at approximately $6,606,000. Fox Run Management L.L.C. acquired a new stake in ADMA Biologics in the 4th quarter valued at approximately $328,000. KLP Kapitalforvaltning AS bought a new position in ADMA Biologics in the 4th quarter worth approximately $794,000. Finally, Sei Investments Co. lifted its holdings in shares of ADMA Biologics by 147.2% during the fourth quarter. Sei Investments Co. now owns 527,272 shares of the biotechnology company's stock worth $9,043,000 after buying an additional 314,013 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.

Remove Ads

ADMA Biologics Stock Performance

ADMA stock traded down $0.02 during trading on Friday, reaching $20.26. 2,360,170 shares of the stock were exchanged, compared to its average volume of 3,517,452. ADMA Biologics, Inc. has a twelve month low of $5.90 and a twelve month high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $4.79 billion, a P/E ratio of 72.36 and a beta of 0.60. The stock has a 50 day simple moving average of $17.13 and a 200-day simple moving average of $18.15.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.